Header Logo

Connection

PAVAN REDDY to Acute Disease

Back to Details
This is a "connection" page, showing publications PAVAN REDDY has written about Acute Disease.
PAVAN REDDY
Connection Strength
1.208
Acute Disease
  1. a1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease. Blood. 2018 03 22; 131(12):1372-1379.
    View in: PubMed
    Score: 0.110
  2. Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT. Blood. 2017 10 12; 130(15):1760-1767.
    View in: PubMed
    Score: 0.106
  3. Tissue tolerance: a distinct concept to control acute GVHD severity. Blood. 2017 03 30; 129(13):1747-1752.
    View in: PubMed
    Score: 0.102
  4. Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. Lancet Oncol. 2014 Jan; 15(1):87-95.
    View in: PubMed
    Score: 0.082
  5. Induction of acute GVHD by sex-mismatched H-Y antigens in the absence of functional radiosensitive host hematopoietic-derived antigen-presenting cells. Blood. 2012 Apr 19; 119(16):3844-53.
    View in: PubMed
    Score: 0.071
  6. Immunization with host-type CD8{alpha}+ dendritic cells reduces experimental acute GVHD in an IL-10-dependent manner. Blood. 2010 Jan 21; 115(3):724-35.
    View in: PubMed
    Score: 0.062
  7. GVHD pathophysiology: is acute different from chronic? Best Pract Res Clin Haematol. 2008 Jun; 21(2):101-17.
    View in: PubMed
    Score: 0.056
  8. Combined Th2 cytokine deficiency in donor T cells aggravates experimental acute graft-vs-host disease. Exp Hematol. 2008 Aug; 36(8):988-96.
    View in: PubMed
    Score: 0.056
  9. Biological advances in acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Transplantation. 2008 Feb 15; 85(3):303-8.
    View in: PubMed
    Score: 0.055
  10. Pathophysiology of acute graft-versus-host disease: recent advances. Transl Res. 2007 Oct; 150(4):197-214.
    View in: PubMed
    Score: 0.053
  11. Paradoxical effects of interleukin-18 on the severity of acute graft-versus-host disease mediated by CD4+ and CD8+ T-cell subsets after experimental allogeneic bone marrow transplantation. Blood. 2004 Nov 15; 104(10):3393-9.
    View in: PubMed
    Score: 0.043
  12. Immunobiology of acute graft-versus-host disease. Blood Rev. 2003 Dec; 17(4):187-94.
    View in: PubMed
    Score: 0.041
  13. Pathophysiology of acute graft-versus-host disease. Hematol Oncol. 2003 Dec; 21(4):149-61.
    View in: PubMed
    Score: 0.041
  14. Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects. Blood. 2003 Apr 01; 101(7):2877-85.
    View in: PubMed
    Score: 0.038
  15. Prevention and Treatment of Acute Graft-versus-Host Disease in Children, Adolescents, and Young Adults. Biol Blood Marrow Transplant. 2020 05; 26(5):e101-e112.
    View in: PubMed
    Score: 0.031
  16. The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. Blood Adv. 2019 12 10; 3(23):4034-4042.
    View in: PubMed
    Score: 0.031
  17. Assessment of Individual versus Composite Endpoints of Acute Graft-versus-Host Disease in Determining Long-Term Survival after Allogeneic Transplantation. Biol Blood Marrow Transplant. 2019 08; 25(8):1682-1688.
    View in: PubMed
    Score: 0.029
  18. Acute Graft-versus-Host Disease: Novel Biological Insights. Biol Blood Marrow Transplant. 2016 Jan; 22(1):11-6.
    View in: PubMed
    Score: 0.023
  19. Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014 Sep; 20(9):1426-34.
    View in: PubMed
    Score: 0.021
  20. Role of cytokines in the pathophysiology of acute graft-versus-host disease (GVHD): are serum/plasma cytokines potential biomarkers for diagnosis of acute GVHD following allogeneic hematopoietic cell transplantation (Allo-HCT)? Curr Stem Cell Res Ther. 2012 May; 7(3):229-39.
    View in: PubMed
    Score: 0.018
  21. Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease. Biol Blood Marrow Transplant. 2010 Jul; 16(7):907-14.
    View in: PubMed
    Score: 0.016
  22. Emerging drugs for acute graft-versus-host disease. Expert Opin Emerg Drugs. 2009 Jun; 14(2):219-32.
    View in: PubMed
    Score: 0.015
  23. Graft-versus-host disease. Lancet. 2009 May 02; 373(9674):1550-61.
    View in: PubMed
    Score: 0.015
  24. A biomarker panel for acute graft-versus-host disease. Blood. 2009 Jan 08; 113(2):273-8.
    View in: PubMed
    Score: 0.014
  25. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood. 2008 Feb 15; 111(4):2470-5.
    View in: PubMed
    Score: 0.014
  26. Critical role of host gammadelta T cells in experimental acute graft-versus-host disease. Blood. 2005 Jul 15; 106(2):749-55.
    View in: PubMed
    Score: 0.011
  27. Both perforin and Fas ligand are required for the regulation of alloreactive CD8+ T cells during acute graft-versus-host disease. Blood. 2005 Mar 01; 105(5):2023-7.
    View in: PubMed
    Score: 0.011
  28. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol. 2004 Jun 15; 172(12):7393-8.
    View in: PubMed
    Score: 0.011
  29. Role of CXCR3-induced donor T-cell migration in acute GVHD. Exp Hematol. 2003 Oct; 31(10):897-902.
    View in: PubMed
    Score: 0.010
  30. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med. 2002 Jun; 8(6):575-81.
    View in: PubMed
    Score: 0.009
  31. Flt3 ligand therapy for recipients of allogeneic bone marrow transplants expands host CD8 alpha(+) dendritic cells and reduces experimental acute graft-versus-host disease. Blood. 2002 Mar 01; 99(5):1825-32.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.